Why a small cartilage defect still needs a real decision

A small cartilage defect can feel like a minor finding — and for a while it may produce only intermittent discomfort. The difficulty is that articular cartilage has no blood supply and almost no ability to repair itself, which means a symptomatic full-thickness lesion (ICRS grade III or IV, meaning damage reaching down to or through the deepest cartilage layer) will not settle on its own. Studies tracking untreated focal chondral lesions have found radiographic osteoarthritis in the majority of cases at 20-year follow-up — a meaningful long-term cost for what looks at first like a contained problem.

Defect size matters for treatment choice. A lesion under approximately 2.5 cm² sits within the working range of both options discussed here: OATS (Osteochondral Autograft Transfer System), a surgical procedure that transplants the patient's own bone and cartilage into the defect, and the ChondroFiller injection, an outpatient ultrasound-guided treatment that places a resorbable collagen scaffold directly into the lesion without theatre or general anaesthetic. Neither is a pain-management injection — both are aimed at structural repair of the defect itself.

Both also require a reasonably healthy surrounding joint. The starting point for any decision is confirming the defect is focal and contained, not part of diffuse or multi-compartment disease.

How OATS works and what recovery involves

During OATS, the surgeon removes one or more cylindrical plugs of bone and cartilage from a lower-load area of the same knee — typically the peripheral femoral condyle — and press-fits them directly into the defect. No donor knee is needed, and no cell culture or second operation is required: the graft is harvested and implanted in a single theatre session. For defects under approximately 2 cm², a single plug of 8–10 mm diameter usually fills the lesion. Larger defects up to around 4 cm² may require mosaicplasty — tiling the area with several smaller plugs — though this approach carries a slightly higher risk of fibrocartilage ingrowth in the spaces between plugs, which reduces the coverage quality compared with a single-plug transfer.

The key structural advantage is tissue type. The transplanted surface is genuine hyaline cartilage — the same smooth, load-bearing material found in a healthy knee — rather than the fibrocartilage scar that forms after bone-marrow stimulation techniques such as microfracture. That distinction matters for long-term durability.

Outcomes

A 2026 retrospective case series of 63 patients (mean age 27.4 years; mean lesion size 2.3 cm²; mean follow-up 5.7 years) recorded IKDC scores rising from 46.4 before surgery to 78.0 at five years (P<.001). A large synthesis by Pareek et al. places overall long-term success at approximately 72%, with 92% of competitive athletes returning to sport.

Recovery

Recovery requires a genuine commitment. Patients are non-weight-bearing for approximately six weeks and typically use a continuous passive motion (CPM) device for several hours daily during that period to maintain range of motion. Full functional recovery generally takes three to six months. The overall reoperation rate in published series is 19–28%, and donor-site morbidity — anterior knee pain, stiffness, or mechanical symptoms from the harvest site — affects approximately 6.7–10.8% of patients, though some surgeons now back-fill the harvest site with synthetic plugs to reduce this risk.

Who OATS is not suitable for

OATS has relative contraindications that rule it out for a meaningful proportion of patients. Age over 50, BMI above 40, established knee osteoarthritis beyond Kellgren-Lawrence grade 2, and a history of inflammatory arthritis, infection, or tumour are each reasons a consultant is likely to consider alternative pathways. Patients for whom a six-week period of non-weight-bearing is not feasible — due to work, caring responsibilities, or comorbidities — also need to weigh this carefully before proceeding.

How the ChondroFiller injection works and what to expect

Patients attend as outpatients, receive a single ultrasound-guided injection into the cartilage defect, and leave the same day — no anaesthetic, no incision, no hospital admission required.

What happens inside the joint is more intricate. ChondroFiller injection delivers an acellular type I collagen liquid that, at the knee's neutral pH, polymerises within approximately 3–5 minutes to form a stable three-dimensional scaffold that fills the defect precisely. That scaffold does two things simultaneously: it provides a structural environment into which the body's own progenitor cells — including mesenchymal stem cells — can migrate and begin regenerating tissue, and it suppresses MMP-13, a cartilage-degrading enzyme that would otherwise undermine the repair process. As host tissue establishes itself, the collagen matrix gradually resorbs.

What the published data show

Across published knee studies, IKDC scores rise from a baseline of approximately 48 to around 80 at three years — a gain of roughly 30 points — with statistically significant improvement typically emerging by three months. MRI at one year consistently shows meaningful structural fill, with MOCART regeneration scores of 70–87 out of 100. Approximately 80% of patients report good or very good results. Over 19,000 ChondroFiller procedures have been performed globally.

Important limitations

The ChondroFiller injection is designed for focal, contained lesions in an otherwise reasonably healthy joint. It is not appropriate for diffuse osteoarthritis or bone-on-bone disease, where the broader joint environment cannot support the repair process.

In the UK, the treatment is not funded by the NHS and is not covered by Bupa or AXA Health. Patients access it on a self-funded private basis; European clinic costs typically fall between €2,500 and €4,500.

What the evidence shows — outcomes side by side

On headline outcome scores, the two pathways look strikingly similar. OATS produced IKDC gains from 46.4 to 78.0 at a mean five-year follow-up in a 2026 case series of 63 patients with lesions averaging 2.3 cm²; the overall long-term success rate in synthesis data sits at approximately 72%, with 92% of competitive athletes returning to sport. ChondroFiller injection produces comparable IKDC gains of roughly 30 points across published knee studies, with 70–85% of treated patients achieving meaningful symptom relief at three to five years, and approximately 80% reporting they would repeat the procedure.

Those figures, however, are not directly interchangeable. Follow-up periods differ considerably: OATS has published series extending to 5–10 years, while most ChondroFiller evidence reaches three to five years, with limited data beyond that window. Patient populations and study designs also differ. Critically, no direct head-to-head randomised controlled trial comparing OATS against ChondroFiller injection exists for defects in the ≤2.5 cm² range — a genuine evidence gap, not a reason to dismiss either option.

The majority of ChondroFiller trials to date have been manufacturer-sponsored. This does not invalidate the outcome data, but it is context worth noting when calibrating confidence levels.

One distinction carries particular weight over the longer term: tissue quality. OATS transfers genuine hyaline cartilage, a known structural advantage for durability. The repair tissue supported by ChondroFiller's scaffold is less fully characterised in published histological studies — systematic biopsy follow-up is limited. The mechanism, which recruits progenitor cells including mesenchymal stem cells, is consistent with hyaline-like repair tissue rather than the fibrocartilage scar that forms after microfracture; but whether that potential is reliably achieved in practice remains an open question.

Both pathways show credible functional improvement in well-selected patients. The right choice turns on individual factors addressed in the next section.

Which option suits your situation

The decision rarely comes down to one factor alone. A consultant weighing this up will consider age, activity level, body mass index, background joint health, anaesthetic fitness, and what a post-operative recovery actually looks like in your daily life.

OATS tends to suit younger, highly active patients — typically under 50 — who prioritise long-term structural durability and are working toward full return to sport. Competitive athletes in particular benefit from hyaline cartilage that can absorb repetitive high-load demands. NHS surgical access makes the cost barrier lower, though waiting times are a practical consideration. The trade-off is a recovery measured in months: non-weight-bearing and progressive rehabilitation that demands dedicated support at home.

ChondroFiller injection tends to suit patients for whom the surgical pathway is less straightforward. Contraindications to OATS — a BMI above 40, age above 50, or background knee osteoarthritis beyond Kellgren-Lawrence grade 2 — rule out a meaningful proportion of patients; for this group, ChondroFiller injection may be the only restorative option short of joint replacement. It is also the more practical route for anyone who cannot feasibly step back from work or caring responsibilities for weeks at a time, or for whom general anaesthesia carries additional risk. Being self-funded (as noted earlier) is a real factor for many UK patients.

Where joint loading is uneven — due to leg alignment or a worn compartment — neither option will perform optimally without addressing the mechanical environment first; a consultant may discuss whether alignment correction plays a role.

For patients uncertain which profile they fit, a structured assessment with imaging review is the most reliable next step. Self-locating in a comparison article is a useful starting point; clinical decision-making requires individual evaluation.

Getting the right assessment at Lincolnshire Knee

Choosing between a surgical procedure and an injectable scaffold is not a decision that should rest on a comparison article alone. What matters clinically is a precise characterisation of the defect — its size, depth, and cartilage grade — alongside an honest picture of the surrounding joint, leg alignment, and the patient's realistic activity demands and recovery capacity.

A structured assessment may include objective biomechanical evaluation using MAI Motion® to identify load-distribution patterns, and AI-assisted MRI cartilage analysis via onMRI™ — including T2 mapping and cartilage and meniscus segmentation — to map the defect before any recommendation is made. Both OATS and ChondroFiller injection are available within the MSK Doctors group, and the appropriate pathway is matched to the individual's clinical profile rather than offered as a default.

Lincolnshire Knee is part of that group and sees patients at Sleaford NG34 and Grantham NG31 without GP referral and without NHS-style waiting times. To arrange an assessment, visit lincolnshireknee.co.uk.